NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free ORGS Stock Alerts $0.58 +0.04 (+7.41%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.5850-Day Range$0.46▼$0.6152-Week Range$0.25▼$1.50Volume59,251 shsAverage Volume36,591 shsMarket Capitalization$19.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends Get Orgenesis alerts: Email Address Orgenesis MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.60% of Shares Sold ShortDividend StrengthN/ASustainability-1.49Upright™ Environmental ScoreNews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector366th out of 915 stocksPharmaceutical Preparations Industry167th out of 430 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Orgenesis.Read more about Orgenesis' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.60% of the outstanding shares of Orgenesis have been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orgenesis has recently decreased by 17.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOrgenesis has received a 66.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Gene therapy medication", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Orgenesis is -1.49. Previous Next 3.6 News and Social Media Coverage News SentimentOrgenesis has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Orgenesis this week, compared to 0 articles on an average week.Search Interest1 people have searched for ORGS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Orgenesis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.66% of the stock of Orgenesis is held by insiders.Percentage Held by InstitutionsOnly 22.56% of the stock of Orgenesis is held by institutions.Read more about Orgenesis' insider trading history. Previous Next N/A Earnings and Valuation Read more about Orgenesis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Orgenesis Stock (NASDAQ:ORGS)Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Read More ORGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORGS Stock News HeadlinesMay 31, 2024 | investorplace.comORGS Stock Earnings: Orgenesis Reported Results for Q4 2023May 21, 2024 | investorplace.comORGS Stock Earnings: Orgenesis Misses Revenue for Q1 2024May 21, 2024 | globenewswire.comOrgenesis Provides Business Update for the First Quarter of 2024April 17, 2024 | investing.comOrgenesis secures $2.3 million investment and strategic partnershipApril 17, 2024 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 15, 2024 | globenewswire.comOrgenesis Provides Year End Business UpdateApril 11, 2024 | investing.comGermfree partners with Orgenesis to enhance CGT productionApril 10, 2024 | globenewswire.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityMarch 18, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMarch 13, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesMarch 4, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementFebruary 29, 2024 | globenewswire.comOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingFebruary 23, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS)February 22, 2024 | morningstar.comOrgenesis Inc ORGSJanuary 31, 2024 | msn.comEXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To ClinicJanuary 31, 2024 | finance.yahoo.comOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicJanuary 8, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo FinanceNovember 22, 2023 | finance.yahoo.comAnalysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven SoonNovember 15, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNovember 13, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the Third Quarter of 2023November 8, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNovember 5, 2023 | forbes.com6 Secrets Of Organizations That Successfully Adapt To ChangeNovember 2, 2023 | finance.yahoo.comOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingOctober 31, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public OfferingSee More Headlines Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/21/2024Today6/15/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees146Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-1,343.97% Pretax Margin-692.54% Return on Equity-924.61% Return on Assets-503.42% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$530,000.00 Price / Sales37.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-0.88Miscellaneous Outstanding Shares34,450,000Free Float32,497,000Market Cap$19.97 million OptionableOptionable Beta1.20 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Vered Caplan M.Sc. (Age 55)Chairperson of the Board, CEO & President Comp: $341.38kProf. Sarah Ferber Ph.D. (Age 70)Founder & Chief Scientific Officer Comp: $268.32kMr. Victor Miller (Age 54)CFO, Secretary & Treasurer Pierre LammeretzInterim Chief Operating OfficerDr. Shimon Hassin Ph.D.Chief Technology OfficerMr. Evan FishmanChief Financial Officer of Orgenesis BiotechMr. Joseph CarpinelliChief Financial Officer of OctomeraMore ExecutivesKey CompetitorsChembio DiagnosticsNASDAQ:CEMIRallybioNASDAQ:RLYBViveon Health AcquisitionNYSE:VHAQGeneluxNASDAQ:GNLXMediciNovaNASDAQ:MNOVView All CompetitorsInsidersJacob SafierBought 10,100 shares on 2/1/2024Total: $3,333.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/30/2024Total: $8,250.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/25/2024Total: $8,000.00 ($0.32/share)Jacob SafierBought 10,000 shares on 1/22/2024Total: $2,900.00 ($0.29/share)Jacob SafierBought 10,000 shares on 1/18/2024Total: $3,300.00 ($0.33/share)View All Insider Transactions ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed in 2024? Orgenesis' stock was trading at $0.5007 at the beginning of the year. Since then, ORGS stock has increased by 15.8% and is now trading at $0.5798. View the best growth stocks for 2024 here. Are investors shorting Orgenesis? Orgenesis saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 205,400 shares, a drop of 17.6% from the May 15th total of 249,300 shares. Based on an average daily volume of 156,600 shares, the days-to-cover ratio is currently 1.3 days. View Orgenesis' Short Interest. When is Orgenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ORGS earnings forecast. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) released its earnings results on Tuesday, May, 21st. The company reported ($0.29) earnings per share (EPS) for the quarter. The business had revenue of $0.14 million for the quarter. Orgenesis had a negative net margin of 1,343.97% and a negative trailing twelve-month return on equity of 924.61%. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Orgenesis have any subsidiaries? The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.Read More This page (NASDAQ:ORGS) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.